Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
SRI's are considered first-line treatments for OCD, however many patients continue to have
significant symptoms despite an adequate trial of an SRI. Neuroimaging studies have shown
that the glutamate neurological system is involved in OCD. This study will test the safety
and efficacy of topiramate, a drug, which targets glutamate, in the treatment of OCD, where
the OCD has been un-responsive, or partially responsive to regular SRI treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Hamilton Health Sciences Corporation McMaster University
Collaborators:
Hamilton Health Sciences Corporation Janssen-Ortho Inc., Canada